$NBTX News
Last published 2d ago
- 2d agoNBTXNanobiotix to Participate in Investor Conferences in NovemberGlobeNewswirePARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November:
- 2d agoNBTXNanobiotix to Participate in Investor Conferences in NovemberGlobeNewswirePARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients
- 2w agoNBTXNANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous MelanomaGlobeNewswireIn 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety
- 3w agoNBTXVoting Rights and Shares Capital of the CompanyGlobeNewswireIn accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Oct. 20, 2026 (GLOBE
- 1mo agoNBTXNANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung CancerGlobeNewswireAll 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year
- 2mo agoNBTXNANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewswirePARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients
- 2mo agoNBTXVoting Rights and Shares Capital of the CompanyGlobeNewswireIn accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE
- 3mo agoNBTXVoting Rights and Shares Capital of the CompanyGlobeNewswirePARIS, July 30, 2026 (GLOBE NEWSWIRE) -- In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés
- 5mo agoNBTXNanobiotix Provides First Quarter 2026 Operational and Financial UpdateGlobeNewswireCompleted a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company's other platformsNew data from
- 5mo agoNBTXNanobiotix Joins the Euronext Tech Leaders IndexGlobeNewswirePARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients
- 5mo agoNBTXNANOBIOTIX Announces Closing of Global OfferingGlobeNewswirePARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to
- 5mo agoNBTXNANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 MillionGlobeNewswirePARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to
- 5mo agoNBTXNanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext ParisGlobeNewswirePARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to
- 5mo agoNBTXNanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext ParisGlobeNewswirePARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to
- 5mo agoNBTXNanobiotix Announces Launch of Global Follow-On OfferingGlobeNewswirePARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ:NBTX – "Nanobiotix" or the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to
- 5mo agoNBTXNanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerGlobeNewswirePARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients
- 6mo agoNBTXNanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer StudyGlobeNewswirePARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
- 6mo agoNBTXNanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer TechnologyGlobeNewswirePreclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle("LNP")-delivered therapies related to rapid liver clearancePre-treatment with
- 7mo agoNBTXNanobiotix Full Year 2025 Financial ResultsNANOBIOTIX SAEarnings Call TranscriptsGood afternoon and good morning and welcome to the nanobiotics conference call to discuss our full year 2025 financial and operational results. Joining me on the call today are Laurent Levy, co-founder and chief executiv
- 7mo agoNBTXNANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial ResultsGlobeNewswireGlobal development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung
- 7mo agoNBTXNANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung CancerGlobeNewswireData presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company
- 7mo agoNBTXNANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026GlobeNewswirePARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to
- 7mo agoNBTXNANOBIOTIX Statement Regarding Recent Media SpeculationGlobeNewswirePARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients
- 8mo agoNBTXNANOBIOTIX to Participate in Investor Conferences in MarchGlobeNewswirePARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand
- 11mo agoNBTXNANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext ParisGlobeNewswirePARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
- 11mo agoNBTXNanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical OutlookGlobeNewswireFinancial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty ("HCRx") of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3)
- 12mo agoNBTXNANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External CollaborationsGlobeNewswireFour new patent applications filed that aim to expand the Curadigm Nanoprimer platform intellectual property portfolio and support an initial proprietary internal pipeline of Nanoprimer products in addition to external
- 1y agoNBTXNANOBIOTIX to Participate in Jefferies London Healthcare ConferenceGlobeNewswirePARIS and CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand
- 1y agoNBTXNANOBIOTIX to Participate in Investor Conferences the Week of November 10thGlobeNewswirePARIS and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ:NBTX - the "Company"), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand
- 1y agoKKRNBTXNANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term GrowthGlobeNewswire$71 million in funding would extend Nanobiotix cash visibility into early 2028Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancerFinancing establishes financial
- 1y agoNBTXNANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational ControlGlobeNewswirePARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand
- 1y agoGTBPIMABENGNONCO+1Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment ParadigmsPR NewswireEquity InsiderNews Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are...
- 1y agoNBTXNANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal CancerGlobeNewswireTreatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6
- 1y agoNBTXNANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial ResultsGlobeNewswirePARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients
- 1y agoNBTXNANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCCGlobeNewswireTreatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate ("DCR") and 37% (15/41) objective
- 1y agoNBTXNanobiotix S.A. (NBTX) Discusses On New Phase 1 Results In Metastatic Melanoma Conference (Transcript)Earnings Call Transcripts
- 1y agoNBTXNANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1GlobeNewswireData show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D)
- 1y agoNBTXNanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswirePARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to
- 1y agoNBTXNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)GlobeNewswireHealth authorities in major European countries have accepted the reclassification of JNJ-1900 (NBTXR3) from a medical device to a medicinal product, aligning with regulatory status in the US and other major
- 1y agoNBTXNANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ConferenceGlobeNewswirePARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand
- 1y agoNBTXNanobiotix Provides First Quarter 2025 Operational and Financial UpdateGlobeNewswireDosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference
- 1y agoNBTXNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQGlobeNewswirePARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand
- 1y agoNBTXNanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic CancerGlobeNewswireResults demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months
- 1y agoNBTXNanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference CallGlobeNewswireFull results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable
- 1y agoNBTXNANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial ResultsGlobeNewswireGlobal development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined
- 1y agoNBTXNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025GlobeNewswirePARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to
- 1y agoNBTXNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLCGlobeNewswireData show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of survival data showed
- 1y agoNBTXNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer ConferenceGlobeNewswireData evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable,
- 1y agoNBTXNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026GlobeNewswirePARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches
- 1y agoNBTXNanobiotix to Participate in Multiple Investor Conferences in February and March 2025GlobeNewswirePARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand